If you have a certain kind of cancer or tumor, your doctor may prescribe Xgeva to help prevent serious bone problems. Xgeva is a prescription drug that’s used in adults to: Doctors may also prescribe ...
MADRID, Dec. 22, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ: ...
Basel, March 5, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Wyost® (denosumab-bbdz) and Jubbonti® ...
Zoledronate infusion preserves BMD gains after denosumab discontinuation for women with osteoporosis
Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...
"Today's approval of XGEVA illustrates what is possible when scientific innovation, commitment and investment come together to advance medicine," said Kevin Sharer, chairman and chief executive ...
The European Medicines Agency (EMA) accepted to review Sandoz's applications for a proposed biosimilar to denosumab. The applications by Sandoz — Novartis' (NYSE:NVS) generic and biosimilars unit — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback